Linked e-resources
Details
Table of Contents
The public health impact of the diabetes epidemic
Risk factors
Diabetic nephropathy
Coronary heart disease and diabetes
Diabetes and cerebrovascular disease
Erectile dysfunction
Evidence-based interventions to prevent or retard vascular complications
Classification and clinical features of neuropathy
Pathophsiology [sic] of diabetic neuropathy
Epidemiology and natural history of DPN
Detections/screenings/assessment
Foot ulceration and charcot arthropathy
Treatment options
Management guidelines for diabetic peripheral neuropathy and foot ulceration
Diabetic retinopathy: epidemiology and risk factors
Classification and diagnosis of diabetic retinopathy
Diabetic maculopathy
Proliferative diabetic retinopathy
Non-retinal diabetic ocular complications
Pathophysiology & potential targets for therapeutic intervention
Protein kinase C
PKC activation & vascular permeability
Role of PKC activation in cardiovascular and renal complications of diabetes
Experimental pharmacology using isoform-selective PKC inhibitors
Clinical trials with ruboxistaurin.
Risk factors
Diabetic nephropathy
Coronary heart disease and diabetes
Diabetes and cerebrovascular disease
Erectile dysfunction
Evidence-based interventions to prevent or retard vascular complications
Classification and clinical features of neuropathy
Pathophsiology [sic] of diabetic neuropathy
Epidemiology and natural history of DPN
Detections/screenings/assessment
Foot ulceration and charcot arthropathy
Treatment options
Management guidelines for diabetic peripheral neuropathy and foot ulceration
Diabetic retinopathy: epidemiology and risk factors
Classification and diagnosis of diabetic retinopathy
Diabetic maculopathy
Proliferative diabetic retinopathy
Non-retinal diabetic ocular complications
Pathophysiology & potential targets for therapeutic intervention
Protein kinase C
PKC activation & vascular permeability
Role of PKC activation in cardiovascular and renal complications of diabetes
Experimental pharmacology using isoform-selective PKC inhibitors
Clinical trials with ruboxistaurin.